GlassScriptPhysician profile
Jack Thomas Sutcliffe
NPI 1548849623
$1,435.45
in general payments reported to CMS, 2019-2025
28 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $82.37 · 2024: $283 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $263.26 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $165.00 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $142.82 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $87.47 | 2024-2025 | |
| Exact Sciences Corporation | $84.76 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $82.37 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $76.88 | 2024-2025 | |
| Alkermes, INC. | $55.78 | 2025 | Vivitrol |
| Lilly USA, LLC | $42.07 | 2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.75 | 2025 | Xifaxan |
| Pfizer INC. | $35.54 | 2024-2025 | |
| Viatris Specialty LLC | $33.96 | 2025 | Yupelri |
| Averitas Pharma INC. | $32.41 | 2025 | Qutenza |
| Tolmar, INC. | $30.63 | 2025 | Jatenzo |
| Amgen INC. | $28.38 | 2024-2025 | Otezla, Repatha, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $24.96 | 2025 | Senza |
| Daiichi Sankyo INC. | $24.60 | 2024 | Injectafer |
| Abbott Laboratories | $23.88 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $18.03 | 2024 | Korlym |
| Cvrx, INC. | $17.90 | 2024 | Barostim Neo System |
| Lundbeck LLC | $17.80 | 2025 | Rexulti |
| Cequr Corporation | $16.88 | 2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $16.42 | 2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $15.96 | 2024 | Gvoke Hypopen |
| Sonex Health, INC. | $14.96 | 2025 | Sx-One Microknife |
| Novartis Pharmaceuticals Corporation | $14.58 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.54 | 2024 | |
| Phathom Pharmaceuticals, INC. | $12.86 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Sutcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.